Valuation: Semler Scientific, Inc.

Market Cap 311M 272M 250M 233M 441M 29.59B 448M 3B 1.17B 14.54B 1.17B 1.14B 50.12B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 311M 272M 250M 233M 441M 29.59B 448M 3B 1.17B 14.54B 1.17B 1.14B 50.12B EV / Sales 2026 *
9.59x
EV / Sales 2027 * -
Free-Float
97.04%
Yield 2026 *
-
Yield 2027 * -
1 day-4.87%
6 months+14.34%
Current year+32.96%
Current year 15.45
Extreme 15.45
24.19
1 year 14.88
Extreme 14.885
48.77
3 years 14.88
Extreme 14.885
81.56
5 years 14.88
Extreme 14.885
153.21
10 years 1.28
Extreme 1.28
153.21
Manager TitleAgeSince
Chief Operating Officer - 2022-11-30
Chief Tech/Sci/R&D Officer - -
Corporate Secretary 45 2026-01-15
Director TitleAgeSince
Director/Board Member 41 2026-01-15
Date Insider Type Main position Quantity % Market Cap.
01-15Issuer sale

Director

867,449 5.6751%
01-15Issuer sale

Chief Executive Officer

596,303 3.9012%
01-15Issuer sale

Director

31,220 0.2043%
Change 5-day change 1-year change 3-year change Capi.($)
-4.87%-.--%-49.74%-22.37% 311M
+0.68%+0.61%+26.89%-5.96% 12.53B
+2.20%+3.73%+64.78%+37.36% 6.36B
+1.56%+5.29%+7.24%+11.92% 5.87B
+2.63%+9.48% - - 4.38B
-0.16%+7.39%-33.87%+6.45% 4.05B
+1.60%+3.99%-25.95%-26.03% 3.91B
+9.00%+11.47%-2.88%-59.39% 1.99B
+1.43%+4.40%+30.75%+241.52% 1.88B
+0.94%+0.54%+56.10%-7.11% 1.55B
Average +1.50%+4.16%+8.15%+19.60% 4.28B
Weighted average by Cap. +1.62%+3.56%+17.58%+12.35%

Financials

2026 *2027 *
Net sales 32.4M 28.32M 26.03M 24.26M 46.02M 3.08B 46.72M 312M 121M 1.52B 122M 119M 5.23B -
Net income - -
Net Debt - -
Logo Semler Scientific, Inc.
Semler Scientific, Inc. is engaged in developing and marketing technology products and services to healthcare providers to combat chronic diseases. The Company's flagship product, QuantaFlo, which is patented and cleared by the United States Food and Drug Administration (FDA), is a rapid point-of-care test that measures arterial blood flow in the extremities. The QuantaFlo test aids in the diagnosis of cardiovascular diseases, such as peripheral arterial disease (PAD), and the Company is seeking a new 510(k) clearance for expanded-indications. QuantaFlo is used by healthcare providers to evaluate their patient's risk of mortality and major adverse cardiovascular events (MACE). QuantaFlo features a sensor clamp that is placed on the toe or finger. A blood flow waveform is instantaneously constructed by its software algorithm. The Company delivers QuantaFlo directly to its customers. The Company also invests in bitcoin and has adopted Bitcoin as its primary treasury asset.
Employees
79
  1. Stock Market
  2. Stocks
  3. SMLR Stock